Table 1 MMP plasma and CD8 immune activation levels in RRMS patients and healthy donors.

From: Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients

 

HD

RRMS

Natalizumab infusion number

0

3

6

12

15

18

24

MMP-9

0.07

[0.01–0.14]

0.10

[0.06–0.16]

0.08

[0.06–0.13]

0.09

[0.08–0.14]

0.08

[0.05–0.15]

0.11

[0.08–0.16]

0.12

[0.06–0.22]

0.15

[0.09–0.23]

MMP-2

0.06

[0.04–0.07]

0.08

[0.06–0.09]

0.07

[0.06–0.09]

0.07

[0.07–0.09]

0.07

[0.06–0.09]

0.08

[0.07–0.09]

0.082

[0.08–0.10]

0.07

[0.06–0.09]

MMP-9/MMP-2

1.14

[0.73–1.77]

1.61

[0.80–2.28]

1.44

[0.62–2.18]

1.35

[1.07–1.93]

1.32

[0.66–2.16]

1.38

[1.05–2.88]

1.46

[0.62–2.68]

1.90

[1.24–2.92]

CD8 HLA-DR+CD38+

0.95

[0.64–1.9]

1.59

[0.94–2.24]

4.17

[2.60–5.71]

2.93

[1.49–4.34]

1.97

[1.32–3.54]

3.21

[2.20–4.96]

2.25

[0.81–3.84]

2.95

[1.64–5.44]

  1. MMP levels are expressed as OD × mm2. CD8 immune activation is expressed as percentage of CD8.
  2. HD: heathy donors. RRMS: relapsing-remitting multiple sclerosis. Data are represented as median values and [interquartile range].
Back to article page